Conversely, the absence of PIK3CA mutation in BRCA2 associated MBCs suggests that alternate oncogenic drivers minimally contribute to tumour drive in this group, thus supporting distinct male breast cancer types. The gene discussed is BRCA2; the disease is neoplasm.